预约演示
更新于：2026-06-20
Tobramycin Sulfate
硫酸妥布霉素
更新于：2026-06-20
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1975-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H39N5O13S |
InChIKeyZEUUPKVZFKBXPW-TWDWGCDDSA-N |
CAS号49842-07-1 |
关联
10
项与 硫酸妥布霉素 相关的临床试验NCT04964947
Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?
NCT04662632
A Randomized Controlled Trial of Alternating Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection (PJI) of the Hip or Knee
EUCTR2018-000492-32-DE
Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections
100 项与 硫酸妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 硫酸妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 硫酸妥布霉素 相关的专利（医药）
登录后查看更多信息
8,780
项与 硫酸妥布霉素 相关的文献（医药）2026-03-04NATURAL PRODUCT RESEARCH
Combination therapy of natural products for the treatment of ESKAPE pathogens
Article
作者: Venkatesan, Lekha Sree ; Sathishkumar, Palanivel
A review.Antimicrobial resistance has emerged as a significant global health challenge, particularly with the rise of multidrug-resistant eSKAPe pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) in both community and hospital settings.The combination therapy of baicalein and rifampicin targets S. aureus growth and biofilm formation and Baicalein disrupts biofilm integrity, while rifampicin inhibits bacterial replication, together enhancing the overall antimicrobial efficacy.Quercetin likely disrupts bacterial defense mechanisms, while meropenem targets the bacterial cell wall, leading to a synergistic effect that improves bacterial killing, particularly in strains producing carbapenemase enzymes, thus, it is anticipated that in the near future, combination therapy using natural products might be a promising strategy to combat drug-resistant eSKAPe pathogens.
2026-01-01VETERINARY OPHTHALMOLOGY
Dexamethasone–Antibiotic Interactions in Canine Ocular Bacteria: In Vitro Susceptibility Changes in Common Corneal Infection Pathogens
Article
作者: Jiwoo Park ; Haerin Yoon ; Myeongjee Kwon ; Jungyeon Yong ; Ji Seung Jung ; Jiyi Hwang ; Kyung‐Mee Park ; Hyun Kwon ; Donghee Kim
ABSTRACT:
Objective:
To investigate the impact of dexamethasone on the antibiotic susceptibility of common ocular pathogens in dogs and identify safe antibiotic‐steroid combinations for veterinary ophthalmology.
Methods:
This study utilized 30 bacterial isolates of
Staphylococcus pseudintermedius
,
Streptococcus canis
, and
Pseudomonas aeruginosa
, collected from canine patients with suspected bacterial keratitis. The isolates were tested against 17 antibiotics in the presence of dexamethasone concentrations ranging from 0 to 2 mg/mL. Minimum inhibitory concentrations (MICs) were determined using standardized broth microdilution techniques, and changes in susceptibility were analyzed statistically.
Results:
Dexamethasone administration resulted in a significant increase in resistance for ciprofloxacin, ticarcillin, tobramycin, and ceftiofur in
S. pseudintermedius
; ticarcillin in
S. canis
; and ciprofloxacin and moxifloxacin in
P. aeruginosa
. Despite these increases, amikacin and cefazolin showed minimal impact on resistance when combined with dexamethasone, indicating their potential for safe use in combination therapies.
Conclusion:
The findings highlight the potential for dexamethasone to alter antibiotic susceptibility in canine ocular pathogens. While dexamethasone can increase resistance in certain antibiotics, amikacin and cefazolin appear to be safer options for combination therapy.
2026-01-01ADVANCED MATERIALS
All Drug Glassy Microneedle Patches for Instantaneous Transdermal Delivery
Article
作者: Juan Tao ; Jintao Zhu ; Quanqian Lyu ; Lianbin Zhang ; Yiyan Cheng ; Senbin Chen ; Qiang Chen ; Shuo Du ; Zhihong Huang
Abstract:
Dissolving microneedles (DMNs) are emerging transdermal delivery platforms but rely on water‐soluble polymers as carriers that inherently limit drug‐loading capacity and slow release due to dissolution/diffusion barriers. Formulating drugs directly into robust DMNs is further challenged by crystallization tendencies. Here, a supramolecular engineering strategy enabling carrier‐free antibiotic glass microneedles (GMNs) is presented, leveraging synergistic drug‐sulfate‐water interactions that suppress crystallization and form mechanically stable amorphous networks. Using tobramycin sulfate, monolithic GMNs are achieved with 100%‐drug payload, exceptional strength (Young's modulus 5.1 GPa), and instant transdermal delivery (threefold faster than polymer DMNs). Eliminating polymeric carriers accelerates drug diffusion by 2.6‐fold, enabling deep tissue penetration for efficient biofilm eradication. In vivo evaluation demonstrates that the antibiotic GMNs effectively promote the healing of biofilm‐infected skin wounds in mice and exhibit potent therapeutic efficacy against subcutaneous abscesses. This strategy extends broadly to aminoglycoside antibiotics. By replacing the polymer matrix with supramolecular‐engineered amorphous networks, a next‐generation DMN platform is pioneered that bridges critical gaps in drug‐loading efficiency, dissolution kinetics, and clinical translation for urgent therapeutic applications.
100 项与 硫酸妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 囊性纤维化 | 澳大利亚 | 2009-07-17 | |
| 下呼吸道感染 | 美国 | 2004-07-13 | |
| 脑膜炎 | 美国 | 2004-07-13 | |
| 腹膜炎 | 美国 | 2004-07-13 | |
| 脓毒症 | 美国 | 2004-07-13 | |
| 皮肤和皮肤结构感染 | 美国 | 2004-07-13 | |
| 泌尿道感染 | 美国 | 2004-07-13 | |
| 细菌感染 | 美国 | 1975-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 76 | (VT-X7) | 鏇鬱鏇顧築鏇膚鑰齋積 = 廠觸獵鏇獵範遞衊範膚 製網餘鑰範繭範繭鬱顧 (齋製齋襯淵壓獵壓鏇積, 廠選觸壓簾願糧廠糧襯 ~ 遞遞簾窪憲網糧窪衊構) 更多 | - | 2026-04-21 | ||
antibiotics (Standard of Care) | 鏇鬱鏇顧築鏇膚鑰齋積 = 夢願襯襯選願選繭鏇鏇 製網餘鑰範繭範繭鬱顧 (齋製齋襯淵壓獵壓鏇積, 憲鬱鹹構窪鑰糧廠醖鹽 ~ 鬱繭衊窪餘廠夢鹹衊艱) 更多 | ||||||
临床3期 | - | Tobramycin nebulization solution 300 mg/4 ml (TNS4) | 範遞蓋繭繭廠壓鏇淵遞(襯鏇鹽壓襯網鏇餘艱襯) = 鹽願憲遞選獵鏇網鹹簾 獵積淵淵餘憲壓選襯衊 (醖蓋構選糧夢築糧窪網 ) 更多 | - | 2014-11-01 | ||
Tobramycin 300 mg/5 ml (TNS5) | 範遞蓋繭繭廠壓鏇淵遞(襯鏇鹽壓襯網鏇餘艱襯) = 顧膚襯願憲積醖衊鬱淵 獵積淵淵餘憲壓選襯衊 (醖蓋構選糧夢築糧窪網 ) | ||||||
临床3期 | 324 | (Bramitob) | 廠遞獵艱繭積廠鬱膚積(顧遞廠餘顧簾膚鑰廠選) = 窪窪醖顧餘觸糧獵廠鑰 夢壓膚糧壓願憲淵餘鑰 (鹹遞憲顧遞廠壓網齋觸, 9.52) 更多 | - | 2014-06-20 | ||
(TOBI) | 廠遞獵艱繭積廠鬱膚積(顧遞廠餘顧簾膚鑰廠選) = 夢觸廠鑰願製艱廠鹹艱 夢壓膚糧壓願憲淵餘鑰 (鹹遞憲顧遞廠壓網齋觸, 9.63) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用